These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 28658094)

  • 21. Nonalcoholic fatty liver disease and non-liver comorbidities.
    Manikat R; Nguyen MH
    Clin Mol Hepatol; 2023 Feb; 29(Suppl):s86-s102. PubMed ID: 36603574
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
    Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
    Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The utility of noninvasive scores in assessing the prevalence of nonalcoholic fatty liver disease and advanced fibrosis in type 1 diabetic patients.
    Singh A; Le P; Lopez R; Alkhouri N
    Hepatol Int; 2018 Jan; 12(1):37-43. PubMed ID: 29318450
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased liver stiffness in patients with severe sleep apnoea and metabolic comorbidities.
    Trzepizur W; Boursier J; Le Vaillant M; Ducluzeau PH; Dubois S; Henni S; Abraham P; Aubé C; Calès P; Gagnadoux F;
    Eur Respir J; 2018 Jun; 51(6):. PubMed ID: 29880653
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease.
    Siddiqui MS; Vuppalanchi R; Van Natta ML; Hallinan E; Kowdley KV; Abdelmalek M; Neuschwander-Tetri BA; Loomba R; Dasarathy S; Brandman D; Doo E; Tonascia JA; Kleiner DE; Chalasani N; Sanyal AJ;
    Clin Gastroenterol Hepatol; 2019 Jan; 17(1):156-163.e2. PubMed ID: 29705261
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and its association with cardiovascular disease.
    Vanjiappan S; Hamide A; Ananthakrishnan R; Periyasamy SG; Mehalingam V
    Diabetes Metab Syndr; 2018 Jul; 12(4):479-482. PubMed ID: 29402657
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Obesity and metabolic syndrome as risk factors for the development of non-alcoholic fatty liver disease as diagnosed by ultrasound.
    Petrović G; Bjelaković G; Benedeto-Stojanov D; Nagorni A; Brzački V; Marković-Živković B
    Vojnosanit Pregl; 2016 Oct; 73(10):910-20. PubMed ID: 29327896
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence and Predictors of Non-Alcoholic Fatty Liver Disease in Morbidly Obese South Indian Patients Undergoing Bariatric Surgery.
    Praveenraj P; Gomes RM; Kumar S; Karthikeyan P; Shankar A; Parthasarathi R; Senthilnathan P; Rajapandian S; Palanivelu C
    Obes Surg; 2015 Nov; 25(11):2078-87. PubMed ID: 25835982
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease.
    Staufer K; Halilbasic E; Spindelboeck W; Eilenberg M; Prager G; Stadlbauer V; Posch A; Munda P; Marculescu R; Obermayer-Pietsch B; Stift J; Lackner C; Trauner M; Stauber RE
    United European Gastroenterol J; 2019 Oct; 7(8):1113-1123. PubMed ID: 31662868
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk factors for non-alcoholic fatty liver disease-associated hepatic fibrosis in type 2 diabetes patients.
    Mansour A; Mohajeri-Tehrani MR; Samadi M; Gerami H; Qorbani M; Bellissimo N; Poustchi H; Hekmatdoost A
    Acta Diabetol; 2019 Nov; 56(11):1199-1207. PubMed ID: 31197470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimizing Use of Nonalcoholic Fatty Liver Disease Fibrosis Score, Fibrosis-4 Score, and Liver Stiffness Measurement to Identify Patients With Advanced Fibrosis.
    Chan WK; Treeprasertsuk S; Goh GB; Fan JG; Song MJ; Charatcharoenwitthaya P; Duseja A; Dan YY; Imajo K; Nakajima A; Ho KY; Goh KL; Wong VW
    Clin Gastroenterol Hepatol; 2019 Nov; 17(12):2570-2580.e37. PubMed ID: 30876959
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis.
    Lee YH; Cho Y; Lee BW; Park CY; Lee DH; Cha BS; Rhee EJ
    Diabetes Metab J; 2019 Feb; 43(1):31-45. PubMed ID: 30793550
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE.
    Doycheva I; Cui J; Nguyen P; Costa EA; Hooker J; Hofflich H; Bettencourt R; Brouha S; Sirlin CB; Loomba R
    Aliment Pharmacol Ther; 2016 Jan; 43(1):83-95. PubMed ID: 26369383
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nonalcoholic fatty liver disease diagnosed by transient elastography with controlled attenuation parameter in unselected HIV monoinfected patients.
    Vuille-Lessard É; Lebouché B; Lennox L; Routy JP; Costiniuk CT; Pexos C; Giannakis A; Szabo J; Klein MB; Sebastiani G
    AIDS; 2016 Nov; 30(17):2635-2643. PubMed ID: 27603289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical utility of noninvasive scores in assessing advanced hepatic fibrosis in patients with type 2 diabetes mellitus: a study in biopsy-proven non-alcoholic fatty liver disease.
    Alkayyali T; Qutranji L; Kaya E; Bakir A; Yilmaz Y
    Acta Diabetol; 2020 May; 57(5):613-618. PubMed ID: 31897769
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonalcoholic Fatty Liver Disease and Implications for Older Adults with Diabetes.
    Mantovani A; Targher G; Zoppini G
    Clin Geriatr Med; 2020 Aug; 36(3):527-547. PubMed ID: 32586479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An update on nonalcoholic fatty liver disease.
    Provencher DM
    JAAPA; 2014 Jul; 27(7):18-22. PubMed ID: 24901731
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nonalcoholic fatty liver disease is associated with an increased risk of heart block in hospitalized patients with type 2 diabetes mellitus.
    Mantovani A; Rigolon R; Pichiri I; Bonapace S; Morani G; Zoppini G; Bonora E; Targher G
    PLoS One; 2017; 12(10):e0185459. PubMed ID: 28981521
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence and Predictors of Significant Fibrosis Among Subjects with Transient Elastography-Defined Nonalcoholic Fatty Liver Disease.
    Lee HW; Kim BK; Kim SU; Park JY; Kim DY; Ahn SH; Kim KJ; Han KH
    Dig Dis Sci; 2017 Aug; 62(8):2150-2158. PubMed ID: 28523578
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-alcoholic fatty liver disease is associated with stroke severity and progression of brainstem infarctions.
    Li H; Hu B; Wei L; Zhou L; Zhang L; Lin Y; Qin B; Dai Y; Lu Z
    Eur J Neurol; 2018 Mar; 25(3):577-e34. PubMed ID: 29281159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.